Effects of anti-viral drug (vidarabine) on atrial fibrillation and ventricular arrhythmia

Effects of anti-viral drug (vidarabine) on atrial fibrillation and ventricular arrhythmia - Treatment of arrhythmia by vidarabine

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006026

Enrollment

Registered

2011-08-01

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arrhythmia

Interventions

Effects for atrial arrhythmia Effects for ventricular arrhythmia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Afrial fibrillation Ventricular arrhythmia

Exclusion criteria

Exclusion criteria: Central nervous disease Severe liver dysfunction Severe renal dysfunction

Design outcomes

Primary

Measure	Time frame
1) Time to terminate the atrial fibrillation 2) The decrease number of ventricular arrhythmia	—

Countries

Japan

Contacts

Public ContactYasuhiro Ichikawa

Yokohama City University Cardiovascular Research Institute

junseiri@yokohama-cu.ac.jp045-787-2575

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026